000739.SZ
普洛药业
SZSE · Healthcare · C 制造业 · CN
CNY 19.71
−4.87%Year over year
Reported trailing growth
- Revenue
- -17.8%
- EBITDA
- —
- EBIT
- -11.6%
- EPS
- -13.0%
- Free cash flow
- +89.5%
- Operating cash flow
- +48.9%
Forward estimates
Based on analyst estimates
- Revenue
- +2.4%
- EBITDA
- +34.0%
- EPS
- +65.2%
Three-year CAGR
- Revenue
- -2.5%
- EBITDA
- +7.4%
- EBIT
- +1.9%
- Net income
- -3.4%
- EPS
- -2.9%
- Free cash flow
- +0.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026